

B R O C H U R E | A N N U A L R E P O R T



Bayer Pharmaceutical
Corporate overview brochure



Singulex
Corporate overview brochure



Welcome

Introducing the PROCLEIX® TIGRIS® System — the first and only fully automated, self-contained nucleic acid testing instrument for blood screening. The power of full automation combined with the unique benefits of patented NAT technology provide a greater level of testing capability with less manual labor — hands down.



The PROCLEIX® TIGRIS® System automates all the steps of nucleic acid testing, from sample addition to results reporting. The flexibility of the PROCLEIX TIGRIS System offers increased laboratory efficiency through process controls, safety and minimal hands-on time, all in one small footprint.

The PROCLEIX TIGRIS System features the following:

- Complete NAT Automation** True walk-away capability decreases hands-on time
- Fully Enclosed System** Creates a safe, cGMP environment within a small footprint
- Built-in Process Controls** Ensures consistency and accuracy of system results
- Variable Tube Specifications** Accommodates multiple sample processing methods and tube formats
- Enhanced Testing Capacity** Screens and disinfects on the same platform

Sample Bay

- a. Target Capture Reagent (aTCR) Carousel**
 - Continuous mixing maintains reagent uniformity
 - On-board stability of 60 hours, barcode controlled
 - Capacity to process 2,000 tubes
- b. Pipette Tip Ring**
 - Pipettes can be loaded onto system at any time
 - Tip completion ensures accurate liquid level sensing and clog detection
 - Capacity of 480 tips
- c. Sample Carousel**
 - Tube door allows easy sample access and loading into racks without exposing reagents
 - Barcode identification initiates positive sample ID tracking
 - Capacity of 180 tubes

Computer Workstation

- Monitor, CPU with operating system software and printer included
- Intuitive software allows ease of use
- Every step monitored and controlled by software, ensuring precise operation and accurate results

Multi-Tube Unit (MTU) Drawer


- MTUs can be loaded into system at any time
- Barcoded MTUs contribute to positive sample identification
- Capacity of 20 MTUs (100 tubes)

Multi-Tube Unit (MTU) Waste Container

- Collects deactivated MTUs
- Located in the rear of Waste Drawer
- Capacity of 200 MTUs (1,000 tubes)

Waste Drawer


- Two liquid waste containers and MTU waste container
- Liquid waste tracked by weight
- Capacity of 2,000 tubes of liquid waste



Novartis Product Package
product brochure and sales package for Tigris,
a Novartis blood screening product



Netopia (Motorola)
annual report



Our Vision

Netopia was founded in 1994 with the vision of developing technical platforms which enable business partners to serve the specific needs of small and medium size enterprises (SMEs) with innovative Internet infrastructure technologies. Through its offering of products that are simple to install, configure and use, Netopia has become an acknowledged leader in the industry.

Publicly traded since 1996 (Nasdaq: NTPA), Netopia has enjoyed rapid growth. As technology and markets evolve, Netopia is well positioned for continued success as the only company offering complementary hardware and software products specifically designed for the SME market. Carriers and service providers around the world rely on Netopia products for their SME bundled service offerings.

Headquartered in Alameda, California, Netopia has offices in North America, Europe and Asia. To reach the millions of small and medium size enterprises worldwide, Netopia has established relationships with carriers and service providers such as Comd, Earthlink, France Telecom, MCI WorldCom/USNET, NorthPoint, PSInet, Rhythms, Telecom Italia, Verio, Verizon, and XO. Working closely with these and other industry leaders, we have developed a suite of products and services that, when integrated and marketed as bundled service offerings, enable our partners to generate high margin recurring revenue from their SME customers.

Annual revenue in millions

Year	Revenue (Millions)
1997	\$17
1998	\$20
1999	\$25
2000	\$44
2001	\$90

At Netopia, we understand that small and medium size enterprises (SMEs) need both high-speed Internet connectivity and fast, easy-to-use and economical Web-based business solutions to compete in today's growing wired economy. To dramatically increasing numbers, SMEs are using the Internet to expand their sales and marketing, enhance operations, drive efficiency, and reduce costs.

To meet the expanding needs of the more than 30 million SMEs worldwide, carriers and service providers have evolved their business plans. ISECs, CLECs, ISPs, ASPs, MSPs, ICPs and Web developers are reaching out to SMEs. Netopia is uniquely positioned to equip and support these carriers and service providers with state-of-the-art Internet infrastructure products and services. Our offerings range from high-speed connectivity equipment such as DSL routers and Integrated Access Devices (IADs) to leading-edge Web platforms that enable Internet marketing, e-commerce and e-services. Utilizing this range of offerings, Netopia works closely with service providers to facilitate the creation of product and service bundles designed to improve acquisition and retention of SME clients, while developing high-margin, recurring revenue.

Netopia remains strongly committed to designing innovative technology platforms and providing comprehensive support that empowers our partners to expand their businesses easily and economically.

netopia

Our Vision

Netopia was founded in 1994 with the vision of developing technical platforms which enable business partners to serve the specific needs of small and medium size enterprises (SMEs) with innovative Internet infrastructure technologies. Through its offering of products that are simple to install, configure and use, Netopia has become an acknowledged leader in the industry.

Publicly traded since 1996 (Nasdaq: NTPA), Netopia has enjoyed rapid growth. As technology and markets evolve, Netopia is well positioned for continued success as the only company offering complementary hardware and software products specifically designed for the SME market. Carriers and service providers around the world rely on Netopia products for their SME bundled service offerings.

High-speed connectivity is where we started.

At the core of Netopia's Internet infrastructure strategy is a comprehensive line of high-speed DSL routers and voice-capable Integrated Access Devices (IADs), along with connectivity solutions for T-1, frame relay, cable, ISDN and analog. Our equipment offers sophisticated data management, security and routing capabilities and is easily upgradeable and customizable, allowing end users to readily adopt new technologies.

Value-added services featured in Netopia routers:

- Virtual Private Networks (VPN)
- Firewalls
- Line Bonding
- Integrated Backup

And then we added a range of full-featured Web platforms.

Netopia's Web platforms equip carriers and service providers with the tools to offer turnkey, hosted Web-based solutions to SMEs. More than 50 pre-populated, vertical content packages are available as a part of the Web site and e-Store platform. Carriers and service providers can elect to either self-host the technology platforms or utilize Netopia's expert partner hosting services. Thousands of businesses already rely on Netopia Web platforms for:

- Web sites and overall Internet presence
- Online e-Stores with secure real-time credit card processing
- Web-based customer support and services, including remote help desk

Our focus: Support partner-created service bundles designed to generate higher margin recurring revenue.

In today's competitive markets, service providers face many challenges in improving customer acquisition and retention, and in increasing profitability and revenue – particularly higher margin recurring revenue. Netopia's unique mix of broadband connectivity products and Web platforms provide our partners with unrivaled ability to create and market bundled offerings. These integrated service offerings often include DSL service with VPN and automated backup along with a full-featured hosted Web site and e-Store.

Netopia is the market leader in providing complete Internet infrastructure to small and medium size enterprises.

Netopia is focused on creating leading edge products that enable our partners to meet the Internet infrastructure needs of SMEs. We are dedicated to excellence in implementation and customer support and have an in-depth understanding of the needs of service providers. This focus and dedication has paved the way for Netopia to become recognized as the innovator and leader in the industry.

netopia

Netopia (Motorola)

Corporate overview brochure

L O G O | B R A N D I N G



agent | KOGENATE®

AGENT KOGENATE

a drug anti-counterfeit detection kit for Kogenate



Aerovance

a biopharmaceutical company engaging in the development
and commercialization of medicines for respiratory and allergic diseases



ZEPHYR | **BIOTECH**

Zephyr

a biotech consulting firm specialized
in providing solutions for early stage biotechnology companies



Step Up Reach Out

a program to prepare young adults with hemophilia
to become advocates for their communities



Argonauts

a consulting firm specialized in providing expertise insights and management support and advisory services in launching, building and restructuring high-growth global businesses

P O S T E R | P A C K A G E D E S I G N



Lunigiana

label design for award winning Lunigiana olive oil




Bayer Pharmaceutical

logo, brochure, and package design for Agent Kogenate
a drug anti-counterfeit detection kit



Step Up Reach Out

brochure package and gift items for Step Up Reach Out program,
training young adults with hemophilia to become advocates for their communities



FROM SEQUENCING THE HUMAN GENOME TO DISCOVERING TARGETED BIOMARKERS

LPA

- In WHS, 56% relative risk reduction with aspirin therapy compared with noncarriers
- In WHS, carriers had 15-fold fewer bleeds per CVD event prevented
- In WHS, bleeding events in noncarriers exceeded CVD events prevented by low-dose aspirin therapy (100 mg taken orally on alternate days)

KIF6

- Carriers showed greater statin benefit
(To date, the benefit of statin therapy for KIF6 carriers has only been studied with atorvastatin and pravastatin)
- Carriers found to be at greater risk for CHD events
- NNT to prevent one CHD event with statins was significantly less in carriers than for noncarriers

CHROMOSOME 9P21

References available at the booth and upon request.



KIF6 GENOTYPE

Personalize Your Patient's Therapy

Recent data, not available until recently, have shown that the KIF6 genotype is a powerful predictor of the benefit of statin therapy in patients with CHD. This data was presented at the American Heart Association Scientific Sessions in November 2005.

Genotype	Relative Risk Reduction (%)
KK	~10%
KT	~20%
TT	~30%

Key Findings:

- In WHS, carriers of the KIF6 TT genotype showed a significantly greater benefit from statin therapy compared to noncarriers.
- The benefit of statin therapy was significantly greater in KIF6 TT carriers than in noncarriers.

LPA GENOTYPE

Guiding Personalized Therapy

The LPA gene encodes the major component of apolipoprotein (a) [apo(a)], a lipoprotein that is associated with the development of atherosclerosis. The LPA genotype is a powerful predictor of the benefit of aspirin therapy in patients with CHD. This data was presented at the American Heart Association Scientific Sessions in November 2005.

Genotype	Relative Risk Reduction (%)
LL	~10%
LM	~20%
MM	~30%

Key Findings:

- In WHS, carriers of the LPA MM genotype showed a significantly greater benefit from aspirin therapy compared to noncarriers.
- The benefit of aspirin therapy was significantly greater in LPA MM carriers than in noncarriers.

Celera

10' curve panel and collateral materials for Celera exhibit



BAYER HEALTHCARE



science for a better life

Bayer Pharmaceutical

8' panel and collateral materials for Bayer HR recruitment booth at BayBio



Bayer Pharmaceutical
4x8' presentation posters of development plan

State Medicaid Cost Savings from the
New York University Caregiver Intervention
for Families Coping with Dementia

W. Liang Health Economics Consulting LLC, St. Paul, MN; Department of Health Sciences Research, Mayo Clinic, Rochester, MN; Reports and Forecasts Division, Minnesota Department of Health Services, St. Paul, MN; Department of Psychiatry, New York University School of Medicine, New York, NY; Wolken Consulting LLC, and Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN

OBJECTIVE

The economic burden of long-term care for people with dementia is significant and substantially heavier for Black and Hispanic, than for White, residents. In Wisconsin, nearly one of every two dollars spent on long-term care comes from Black and/or Hispanic residents. These findings suggest that Black and Hispanic residents are disproportionately burdened by the costs of long-term care. Further, the findings suggest that Black and Hispanic residents are disproportionately burdened by the costs of long-term care. Further, the findings suggest that Black and Hispanic residents are disproportionately burdened by the costs of long-term care.

We estimate savings, from the state-proposed program, from offering the New York University (NYU) Internet test (NETIT), a self-administered program, support and counseling programs, to eligible minority students and women.



Introduction

1990 - First AIDS case in the UK
 1991 - First AIDS case in the US
 1992 - First AIDS case in Australia
 1993 - First AIDS case in Canada
 1994 - First AIDS case in New Zealand
 1995 - First AIDS case in South Africa
 1996 - First AIDS case in India
 1997 - First AIDS case in China
 1998 - First AIDS case in Brazil
 1999 - First AIDS case in Russia
 2000 - First AIDS case in Egypt
 2001 - First AIDS case in Iran
 2002 - First AIDS case in Pakistan
 2003 - First AIDS case in Saudi Arabia
 2004 - First AIDS case in Indonesia
 2005 - First AIDS case in Malaysia
 2006 - First AIDS case in Singapore
 2007 - First AIDS case in Thailand
 2008 - First AIDS case in Vietnam
 2009 - First AIDS case in Cambodia
 2010 - First AIDS case in Laos

<p> 1. <i>What is the purpose of the study?</i> 2. <i>What are the research objectives?</i> 3. <i>What is the research design?</i> 4. <i>What is the sample size?</i> 5. <i>What is the data collection method?</i> 6. <i>What is the data analysis method?</i> 7. <i>What are the results of the study?</i> 8. <i>What are the conclusions of the study?</i> 9. <i>What are the limitations of the study?</i> 10. <i>What are the implications of the study?</i> </p>	<p> 1. <i>What is the purpose of the study?</i> 2. <i>What are the research objectives?</i> 3. <i>What is the research design?</i> 4. <i>What is the sample size?</i> 5. <i>What is the data collection method?</i> 6. <i>What is the data analysis method?</i> 7. <i>What are the results of the study?</i> 8. <i>What are the conclusions of the study?</i> 9. <i>What are the limitations of the study?</i> 10. <i>What are the implications of the study?</i> </p>
---	---

Project Information		Project Description		Project Status	
Project Name	Project Manager	Project Start Date	Project End Date	Project Progress (%)	Project Budget (€)
Project A	John Doe	2023-01-01	2023-03-31	75%	100,000
Project B	Jane Smith	2023-02-01	2023-04-30	50%	150,000
Project C	Mike Johnson	2023-03-01	2023-05-31	25%	200,000
Project D	Sarah Brown	2023-04-01	2023-06-30	10%	250,000
Project E	David White	2023-05-01	2023-07-31	5%	300,000
Project F	Emily Green	2023-06-01	2023-08-31	0%	350,000
Project G	Chris Black	2023-07-01	2023-09-30	0%	400,000
Project H	Alexander Grey	2023-08-01	2023-10-31	0%	450,000
Project I	Olivia Blue	2023-09-01	2023-11-30	0%	500,000
Project J	Benjamin Yellow	2023-10-01	2023-12-31	0%	550,000

	Original Price	Market Price	Change in Price
Common stock	100	110	10
Preferred stock	100	100	0
Debt	100	100	0
Equity	200	210	10

The total value of the company's assets is \$210. The total value of the company's liabilities is \$100. The total value of the company's equity is \$110. The total value of the company's debt is \$100. The total value of the company's preferred stock is \$100. The total value of the company's common stock is \$110.

RESULTS

4. The model results in a 100% increase in the number of

- After 17 years, our results suggest approximately 17% lower eligibility with distance when eligibility is based on the 100th birthday in a 50th setting.

44. A corporation has shown cost savings by 100,000 per year with an investment of \$1 million. If the savings are \$1 million per year, the savings are \$1 million per year. (Table 10)

- Substantive WFO programs can be a cost-effective way, improving training and administration improves the culture savings, resulting in net savings and pay savings
- These studies assume all flights completed exactly with least program operate the net cost savings at 10 years are 1.6 million (74% improvement), 1.0-1.2 million (30%), 2.2-1 million (24%), pay (4.3 million (34%))

- **Sensitivity Analysis**
 - Variability in net cash savings was most affected by the NPV25 effect on net savings, with uncertainty differences from \$1.5 million to \$10.6 million, compared to the base case analysis result of \$4.6 million, where we assumed effect was equaling about 55% of the risk of acquisition premium.
 - Major to provide the NPV25 on-cash difference, identifying customer-based costs, are currently being investigated. Assuming this discount effect and approach A, the net savings were \$12.2 million.
 - Best and worst case economic estimates were \$19.8 million and \$2.2 million savings, respectively, following by the variation in the assumed NPV25 effect.

METHOD

Study Design:
Retrospective

- Study dates: April 2012 to May 2013, with data analysis in 2014. *Abstract*
- Background:** General health status and disease amongst the poor remains poorly understood in sub-Saharan Africa from the data generated by the health sector.
- Methods:** We performed a primary analysis of Minnesota Department of Human Services (MHS) data, and the Burden of the Infectious, Non-Communicable, and Mental Health and Substance Abuse (BIMN) data, and the Burden of the Infectious, Non-Communicable, and Mental Health and Substance Abuse (BIMN) data, and the Burden of the Infectious, Non-Communicable, and Mental Health and Substance Abuse (BIMN) data.
- Results:** We found that the burden of disease amongst the poor remains poorly understood from the data generated by the health sector. We found that the burden of disease amongst the poor remains poorly understood from the data generated by the health sector.
- Conclusions:** Our findings suggest that the burden of disease amongst the poor remains poorly understood from the data generated by the health sector.
- Keywords:** General health status, disease amongst the poor, sub-Saharan Africa, data generated by the health sector.

• **Microbiology with concepts** go around by 1

- NI is a smaller senior programs only, state-funded and private-affiliated health care coverage for persons not yet blind and eligible for the SH and/or private health insurance and community-based services in the community aged 65 years or older who reside in the local care provided in a shelter care community residence.

- The WHO has a strong evidence base built on research about:

- Source: © 2012, downloaded from www.scribd.com. All rights reserved. All content on this document is copyrighted by Scribd. All content on this document is copyrighted by Scribd.

Abundance and biomass of benthos: 10th July 2004

1. **Prevalence** was calculated from 999 100 live-born data on screening assessments, eligibility, and claims data

• The likelihood of disease progression and the

- The actual probability of death was based on all cause mortality rates observed among all 986,094 program residents in 2011. We assumed mortality was unaffected by the RFA.

[Download the report](#)

- On average, 400 elements in the 20×20 matrices were calculated for the majority of program executions. In all training and testing, results of experiments for 500 simulations were taken from results of experiments for continuously shifting inputs. The 5000 simulations were divided into two equal parts as well as training and experiments. Experiments were based on time spent for each 1000 as observed in the real, distributed, Mininet implementation. We added constant overhead training and experiments costs based on the managerial model of the Mininet federation of the NFV, in network implementation.

 Springer

- The model includes program, medical and intervention costs separately
- The impact of intervention on costs is displayed at years 1, 5 and 10 to investigate the break-even point at which cumulative costs are considerably lower than savings
- In the absence of a data-driven update rule, we have our results assume all eligible caregivers participate in the MPOC so also our results at varying levels of enrollment
- Additional univariate and scenario sensitivity analysis, including the strength of results



FUNDING

This work was supported in part by the M. D. Anderson Cancer Center, which was made possible through generous gifts from the Howard Foundation, and the American Society of Hematology.

[illegible]

CONCLUSION

Others are, simply, aspects of the broader, growing burden of demands on government budgets, such as health care or ageing population. And because Fisher tries to make savings from corporate tax cuts, the frequently cited line between corporate tax cuts and savings presents a challenge to adoption. It is still not clear how it may be important to distinguish cost effectiveness from impact on treatment outside long-term organizational commitment.

REFERENCE

- [illegible]